Eli Lilly
shares rose early Thursday despite first quarter financial results that came in below estimates, amid good news for the company’s diabetes and obesity drug Mounjaro.
Sales of Mounjaro for the quarter were $568.5 million, well above the $433 million FactSet consensus estimate.
